Show summary Hide summary
Eli Lilly and Company set a Monday deadline for 340B hospitals to submit claims-data documentation or lose access to the drugmaker’s discounted pricing, escalating a months-long dispute over information requirements in the federal 340B Drug Pricing Program.
Quick Facts
- Deadline: Five business days from June 2, ending Monday, June 9, 2026
- Penalty: Loss of 340B discount pricing on all Eli Lilly medications
- Scope: Affects hospitals that have not submitted claims-level data as required
- Launch of requirement: February 1, 2026, from January 15 policy announcement
The 340B Data-Sharing Mandate
Eli Lilly and Company first announced its expanded data requirements in January 2026, effective February 1, requiring all 340B covered entities—including hospitals and other eligible providers—to submit claims-level data for every drug dispensed under the program. According to reporting from Modern Healthcare, Providers that haven’t shared this information will lose access to 340B pricing on Eli Lilly medicines in five business days, or next Monday. The company claims the data is necessary to confirm that hospitals are not double-dipping—receiving discounts while inadvertently billing patients or insurers at full price for the same medications.
The 340B Drug Pricing Program allows eligible hospitals, community health centers, and other covered entities to purchase outpatient drugs at significantly reduced costs. Manufacturers like Eli Lilly set these ceiling prices under federal law, but disputes have erupted over how much visibility drugmakers should have into claims data, which hospitals argue is confidential and burdensome to extract and submit.
Eli Lilly sets Monday deadline for 340B hospitals on data sharing or lose discounts
Insurance rate transparency in Louisiana advances with unanimous votes
Hospital Resistance and Broader Trend
Some hospitals have refused to comply with Eli Lilly’s new data-sharing requirements, arguing the company lacks legal authority to impose them. The American Hospital Association urged the federal Health Resources and Services Administration (HRSA) to block the policy when it was announced, contending that such demands are costly and potentially unworkable for many providers. The ultimatum marks an escalation after months of hospitals resisting the requirement.
Eli Lilly and Company is not alone in the push for data transparency. Other major pharmaceutical manufacturers including Novo Nordisk have announced similar expanded data-reporting requirements for 340B participants, signaling a broader industry trend to strengthen enforcement and reduce what drugmakers see as price-program abuse.
What Hospitals Face Now
Beginning Monday, June 9, any covered entity that has not submitted the required claims data will find itself unable to purchase Eli Lilly and Company medications at 340B prices. Given the importance of discounted drugs to hospital budgets and patient affordability, the deadline carries real teeth. The threat has focused hospitals still holding out to make a rapid decision on whether to comply or absorb higher medication costs.
Sources
- Modern Healthcare — Eli Lilly’s ultimatum to withhold 340B discounts in five business days unless data submitted by June 9
- Fierce Healthcare — Confirmation of Monday deadline and loss of discount access for non-compliant hospitals
- STAT News — Details of five-day submission window and discount loss threat
- American Hospital Association (AHA) — Hospital objections to Lilly’s policy first announced in January 2026
- RWC340B.org — Eli Lilly’s original January 15, 2026 notice and claim that failure to provide timely data may result in cancellation of 340B access
